Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.

Journal of molecular medicine (Berlin, Germany) - 1 Jun 2020

Bao Xuanwen, Shi Run, Zhao Tianyu, Wang Yanfang

Abstract excerpt

Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates and immunotherapy responses. Understanding the immune landscape facilitates the personalized treatment of LUAD. The immune cell populations in tumour tissues were quantified to depict the immune landscape in early-stage LUAD patients in The Cancer Genome Atlas (TCGA). Early-stage LUAD patients in three immune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Decision Trees

Share to Disease Susceptibility

Share to Immunomodulation

Share to Neoplasm Staging

Share to Proportional Hazards Models

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 32333046
DOI: 10.1007/s00109-020-01908-9
PMCID: PMC7297823

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.PMID 32333046Read ↗

Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.Semantic proximity Read ↗

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Semantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.Semantic proximity Read ↗

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinomaSemantic proximity Read ↗

Analysis of Clinical Implications and Immune Landscape in Prognostic Model based on Immune Cell Signatures for Lung Adenocarcinoma PatientsSemantic proximity Read ↗

Immune Score Closely Associated With Tumor Microenvironment as A Prognostic Factor in Lung AdenocarcinomaSemantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of lung adenocarcinomaSemantic proximity Read ↗

The tumor environment immune phenotype of LUSC by genome-wide analysis.Semantic proximity Read ↗

Systematic construction and validation of an immune prognostic model for lung adenocarcinomaSemantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.